Denosumab-Related Osteonecrosis of the Jaw May Not Be a Subject of Teriparatide Treatment

J Bone Miner Res. 2022 Oct;37(10):2044-2045. doi: 10.1002/jbmr.4625. Epub 2022 Jun 25.

Authors

Kyung-Su Park¹, Seung Min Jung¹, Yune-Jung Park¹, Ki-Jo Kim¹

Affiliation

¹ Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea.

PMID: 35751544
DOI: 10.1002/jbmr.4625

No abstract available

Publication types

Letter
Comment

MeSH terms

Bisphosphonate-Associated Osteonecrosis of the Jaw* / drug therapy
Bone Density Conservation Agents*
Denosumab / adverse effects
Diphosphonates
Humans
Osteonecrosis* / chemically induced
Osteonecrosis* / drug therapy
Teriparatide / adverse effects

Substances

Teriparatide
Denosumab
Bone Density Conservation Agents
Diphosphonates